OPGN - OpGen Inc Market Cap to Sales Volume

Corporate company logo of OpGen Corp (OPGN)

OpGen, Inc. (OPGN) management is facing a prolonged crisis due to a severe shortage of funds. Business revenues are based on the sale of Acuitas molecular tests to hospitals. The company's revenue valuation on the GURU.Markets terminal analytical chart clearly demonstrates the trend, where the 6.10 mark shows the current state. However, bankruptcy risk and the slow implementation of diagnostics threaten the very existence of the enterprise.

OpGen Corp (OPGN): Price-to-Revenue Ratio from 07/04/2022 to 08/31/2024

Metric breakdowns and analytics for OpGen Corp (OPGN)

- market price and analyst price targets:
Stock Quotes opgen.com|OPGN - Consensus Target
- market capitalization statistics:
Market Value OpGen Corp|OPGN - Enterprise Value
- book capitalization information:
Net Assets per Share OpGen|OPGN - Company Book Value|Market-to-Book Ratio opgen.com|OPGN - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio OpGen, Inc.|OPGN - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient OpGen Corporation|OPGN - Company Debts|Debts to Book Value OpGen Corp|OPGN - Company Long-Term Debt|Current Liabilities OpGen|Critical Liquidity opgen.com
- net income and valuation ratios data:
OPGN - Net Profit|Expected Net Profit OpGen, Inc.|OPGN - Price to Earnings Ratio|Price to Future Earnings Ratio OpGen Inc|OPGN - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation OpGen Corp|OPGN - Operating profit EBITDA|Net earnings per share for the last four quarters OpGen|OPGN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months opgen.com|OPGN - Earnings growth in current year|Expected earnings per share growth for next year OpGen, Inc.
- total revenue and sales volume data:
OPGN - Company Sales|Company Future Sales opgen.com|OPGN - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio OpGen Corp
Fundamental company analysis:OPGN - opgen.com
Manufactured products of OpGen, Inc.

The price-to-sales ratio allows for an assessment of the market value of a single dollar of revenue, determining the margin of safety and the risk of capital stagnation. For OpGen, Inc. (OPGN), which develops rapid tests against superbugs, median P/S analysis helps align expansion rates within the hospital segment with the asset's current valuation, classifying it as a speculative instrument with high growth potential.

Competitors of OpGen, Inc.

Market Cap to Revenue summittxinc.com SMMT|Moderna - Market Cap to Revenue|Market Cap to Sales Volume PCVX (Vaxcyte Inc)|Tarsus Pharma - P/S Multiple|Price-to-Revenue Coefficient CorMedix Therapeutics CRMD|Seres Therapeutics (MCRB) - Price-to-Revenue Ratio|Price to Sales sperotherapeutics.com (SPRO)|Price-to-Revenue Ratio SCYNEXIS Inc|Market Cap to Revenue Ratio ANTX (AN2 Bio)|Price-to-Revenue Ratio PolyPid Ltd. (PYPD)|Price-to-Revenue Coefficient YS Biopharma Co., Ltd.|Price-to-Revenue Ratio Iterum Therapeutics ITRM|BiomX Inc (PHGE) - Price to Sales|SNGX - Price-to-Revenue Ratio|Price-to-Sales Ratio SXTP|OGEN: P/S Multiple